menu
    • menu

    Company profile for Mycovia Pharmaceuticals

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At Mycovia, we are passionate about developing novel drugs in areas of unmet medical need, with an initial focus in women’s health. Our lead product candidate, VT-1161, is being developed as a treatment for recurrent vulvovaginal candidiasis (RVVC), a debilitating chronic condition that affects millions of women worldwide. More commonly known as a chronic yeast infection, RVVC can severely impact a woman’s physical and emo...
    At Mycovia, we are passionate about developing novel drugs in areas of unmet medical need, with an initial focus in women’s health. Our lead product candidate, VT-1161, is being developed as a treatment for recurrent vulvovaginal candidiasis (RVVC), a debilitating chronic condition that affects millions of women worldwide. More commonly known as a chronic yeast infection, RVVC can severely impact a woman’s physical and emotional well being, and results in billions of dollars in lost productivity. Mycovia currently has three Phase 3 clinical studies being conducted to evaluate VT-1161 for the treatment of RVVC.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Mycovia PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    4505 Emperor Blvd Suite 300 Durham, NC 27703
    Telephone
    Telephone
    919-467-8539
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://mycovia.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/mycovia-pharmaceuticals
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/MycoviaPharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mycovia Publishes 2-Year VIVJOA Results in RVVC Phase 3 Study
    Mycovia Publishes 2-Year VIVJOA Results in RVVC Phase 3 Study

    18 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mycovia-pharmaceuticals-inc-announces-publication-of-2-year-vivjoa-efficacy-results-from-an-extension-of-the-violet-phase-3-studies-in-women-with-recurrent-vulvovaginal-candidiasis-rvvc-in-the-journal-of-womens-health-302617754.html

    PR NEWSWIRE
    18 Nov 2025
    Share Share
    Mycovia Starts Ph2 Study of Cryptococcal Meningitis Treatment
    Mycovia Starts Ph2 Study of Cryptococcal Meningitis Treatment

    04 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mycovia-pharmaceuticals-inc-announces-first-participant-enrolled-in-an-investigator-initiated-phase-2-study-for-cryptococcal-meningitis-302472208.html

    PR NEWSWIRE
    04 Jun 2025
    Share Share
    Mycovia Pharma partners with Jiangsu Hengrui Pharma for Vivjoa
    Mycovia Pharma partners with Jiangsu Hengrui Pharma for Vivjoa

    02 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mycovia-pharmaceuticals-inc-announces-partner-jiangsu-hengrui-pharmaceuticals-co-ltds-recognition-for-the-inclusion-of-vivjoa-oteseconazole-capsules-in-the-chinese-national-reimbursement-drug-list-302417640.html

    PR NEWSWIRE
    02 Apr 2025
    Share Share
    Mycovia Presents VIVJOA® Safety Studies At IDSOG 2024
    Mycovia Presents VIVJOA® Safety Studies At IDSOG 2024

    01 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mycovia-pharmaceuticals-announces-presentation-of-results-from-three-safety-studies-evaluating-vivjoa-oteseconazole-in-subjects-with-renal-or-hepatic-impairment-and-the-impact-on-qt-prolongation-at-the-2024-idsog-annual-meetin-302211538.html

    PR NEWSWIRE
    01 Aug 2024
    Share Share
    Mycovia Announces AllianceRx Walgreens Pharmacy as Distributor of VIVJOA®
    Mycovia Announces AllianceRx Walgreens Pharmacy as Distributor of VIVJOA®

    26 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mycovia-pharmaceuticals-inc-announces-alliancerx-walgreens-pharmacy-and-walgreens-community-based-specialty-pharmacies-as-exclusive-distributor-of-vivjoa-302098255.html

    PR NEWSWIRE
    26 Mar 2024
    Share Share
    Mycovia Announces Partner Jiangsu Hengrui's Commercial Launch of VIVJOA
    Mycovia Announces Partner Jiangsu Hengrui's Commercial Launch of VIVJOA

    07 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mycovia-pharmaceuticals-inc-announces-partner-jiangsu-hengrui-pharmaceuticals-co-ltds-commercial-launch-of-vivjoa-oteseconazole-capsules-for-the-treatment-of-severe-vulvovaginal-candidiasis-vvc-in-china-302046980.html

    PR NEWSWIRE
    07 Feb 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search